Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
about
Aggression in autism spectrum disorder: presentation and treatment optionsAripiprazole for treating irritability in children & adolescents with autism: A systematic reviewAripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-AnalysisThe status of pharmacotherapy for autism spectrum disordersPharmacotherapy to control behavioral symptoms in children with autismPharmacological management in children and adolescents with pervasive developmental disorder.Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study.Aripiprazole in autism spectrum disorders and fragile X syndrome.Retrospective case series of aripiprazole augmentation in pervasive developmental disordersQuetiapine versus aripiprazole in children and adolescents with psychosis--protocol for the randomised, blinded clinical Tolerability and Efficacy of Antipsychotics (TEA) trialYokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study.Aripiprazole for irritability associated with autistic disorder in children and adolescents aged 6-17 years.Focus on aripiprazole: a review of its use in child and adolescent psychiatryOpen-label study comparing the efficacy and tolerability of aripiprazole and haloperidol in the treatment of pediatric tic disorders.Elevated burden for caregivers of children with persistent asthma and a developmental disabilityPharmacologic treatments for the behavioral symptoms associated with autism spectrum disorders across the lifespan.Treatment of inattention, overactivity, and impulsiveness in autism spectrum disordersAripiprazole in the treatment of early-onset schizophrenia spectrum disorder: A case series in Korean children and adolescentsAripiprazole for the treatment of irritability associated with autism.Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.Aripiprazole: a review of its use in the treatment of irritability associated with autistic disorder patients aged 6-17.Overweight and obesity in youth with developmental disabilities: a call to action.The use of antipsychotics in preschoolers: a veto or a sensible last option?Atypical antipsychotics in the treatment of pathological aggression in children and adolescents: literature review and clinical recommendations.A guide to psychopharmacological treatment of patients with intellectual disability in psychiatry.Long-Term Aripiprazole in Youth With Developmental Disabilities Including AutismAripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone.Head-to-Head Comparison of Aripiprazole and Risperidone in the Treatment of ADHD Symptoms in Children with Autistic Spectrum Disorder and ADHD: A Pilot, Open-Label, Randomized Controlled Study.Aripiprazole to treat irritability associated with autism: a placebo-controlled, fixed-dose trial.
P2860
Q26744346-2368AFE9-0424-4B45-ABA5-6A7ACC69633FQ26784199-45EDDAA5-4777-4B11-9E2B-8E66C174A3C7Q28073540-3C1F0EFC-BE5F-4411-A3D1-468073E53E2EQ28239931-B96F83D1-3A0F-482C-8D58-E6AE4AD72ED2Q28265801-D575EE8C-FE13-4521-B5CC-263F90DA867BQ33521748-AE398DF6-8636-463A-9B66-D9EC8E6E2B8FQ33858314-E933042B-B1C0-4D28-A19A-CD336B52C589Q34025492-EC84E63A-3B98-4934-8021-D12CFF65C6E0Q34165087-5A38A9AA-8388-4405-8D90-337744725F9AQ34486230-678260C9-62B2-4DD1-B1E3-BA426BD460FDQ34495483-D40C20AD-E9B3-4F0B-A6B2-E7D711C2C897Q34597411-EC2861B1-E4C1-408E-97E9-4E30D368A753Q34611306-70D6BA7E-78F2-4920-967C-EFDA91912ECAQ34613057-F5173B16-54DC-4532-A353-D260C4D7DF20Q35025775-DCA7D7F4-CD5A-4D80-AB59-C59ADB05E08AQ36443014-7B2C4852-A1B9-4A8A-9F2F-07943F9314C1Q37248753-7164929D-4A38-4AE8-A7CD-9744C95B9A0EQ37667320-53C1B6E0-49FB-414A-AA1F-0DAFB52E0708Q37835845-7293B387-29FC-446B-AB86-08334FF72E34Q38095762-A84B4B12-D4B1-4A03-A2CC-B72F9CC59D0EQ38122151-9FE28BD0-E8AD-4FFF-9AE5-D48BCC8E5CE3Q38135881-9FBB8F0A-AE14-4D0A-A6C4-7404E7B3A9CAQ38180865-2EE0F325-CA9B-46BA-B14D-726B13AA2550Q38448948-93032727-AB77-464D-B0DE-015347FA587DQ38632511-9216A240-1E61-47AA-A6EA-58E88511C33AQ38977828-4F30ECEE-2485-424B-8253-022561E959CDQ46565058-0BE84FD5-0446-4F5A-8B1B-F6D2E0122FDDQ50204761-737B1F54-AA7D-4270-A5B8-183A0E2D3A1EQ50312978-DA73F46A-259A-4FFC-8F8C-28D90BE2AF2C
P2860
Clinical effects and adverse reactions of off-label use of aripiprazole in children and adolescents with developmental disabilities.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Clinical effects and adverse r ...... th developmental disabilities.
@ast
Clinical effects and adverse r ...... th developmental disabilities.
@en
type
label
Clinical effects and adverse r ...... th developmental disabilities.
@ast
Clinical effects and adverse r ...... th developmental disabilities.
@en
prefLabel
Clinical effects and adverse r ...... th developmental disabilities.
@ast
Clinical effects and adverse r ...... th developmental disabilities.
@en
P356
P1476
Clinical effects and adverse r ...... th developmental disabilities.
@en
P2093
Howard Demb
Maria R Valicenti-McDermott
P304
P356
10.1089/CAP.2006.16.549
P577
2006-10-01T00:00:00Z